06/06/2006 (Agence Europe) - The European Commission, the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) have agreed a procedure for joint FDA/EMEA briefing meetings with sponsors following voluntary submission of genomic data by third parties (laboratories and research institutes). Current data confidentiality arrangements will continue to obtain in these meetings. A press release says that much pharmacogenomic data are of an exploratory nature and, in most...